Opendata, web and dolomites

MAINTRAC-Auto

MAINTRAC-Auto: Automatization and validation of a liquid biopsy assay “Maintrac-AUTO CTC-analyser” for predictive real time monitoring and success control of solid tumor cancer therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MAINTRAC-Auto project word cloud

Explore the words cloud of the MAINTRAC-Auto project. It provides you a very rough idea of what is the project "MAINTRAC-Auto" about.

biomarker    ctcs    initial    clinical    death    specialists    therapy    relapse    2020    public    ctc    readiness    maintrac    therapies    implications    individualize    direct    breast    patients    model    automated    track    series    effectiveness    tumor    standardized    patient    arise    commercially    equivalence    appropriate    causes    substantially    launch    regulatory    diseases    precision    business    upscaling    market    drastically    progression    care    estimate    prognosis    offers    indicator    economic    meanwhile    demand    assays    savings    circulating    disease    treatment    diagnose    acceptance    forecasts    12bn    adequately    course    symptoms    maintenance    reducing    suffering    diagnostics    validation    us    manual    approved    ineffective    monitoring    reimbursement    cells    efficiency    auto    meet    innovative    sales    big    automatic    oncology    clinically    penetration    innovation    cancer    primary    assay    families    revenue    individual    analyser    health    worldwide    obvious    relevance   

Project "MAINTRAC-Auto" data sheet

The following table provides information about the project.

Coordinator
SIMFO SPEZIELLE IMMUNOLOGIE FORSCHUNG UND ENTWICKLUNG GMBH 

Organization address
address: KURPROMENADE 2
city: BAYREUTH
postcode: 95448
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.simfo.de
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2016-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SIMFO SPEZIELLE IMMUNOLOGIE FORSCHUNG UND ENTWICKLUNG GMBH DE (BAYREUTH) coordinator 50˙000.00

Map

 Project objective

Worldwide cancer is one of the leading causes of death and the need for more effective therapies is crucial. New precision diagnostics can identify and characterize the disease to individualize the therapy throughout the course of cancer, like our clinically approved Maintrac-CTC assay. Maintrac-CTC can track circulating tumor cells (CTCs) even in primary cancer patients to estimate prognosis and diagnose relapse well before clinical symptoms arise. Meanwhile a fully automated Maintrac AUTO analyser was established and offers a standardized state-of-art biomarker system for direct and better monitoring of disease progression and effectiveness i.e. of the maintenance therapy in breast cancer. We aim to drastically increase both effectiveness (selection of treatment most adequately for individual cancer type and phase) and efficiency (early indicator for the response level to an initial therapy) to avoid ineffective therapies, savings cost for the health care system and substantially reducing patient suffering. The objectives of the innovation project are to achieve series-production readiness and launch the system commercially with the best business model. We aim for acceptance of Maintrac CTC assays by oncology specialists through clinical validation and to achieve reimbursement by public authorities for upscaling and market penetration. In phase 1 we will show equivalence of the automatic system to the established manual method and meet regulatory requirements. In addition business opportunities and appropriate sales model will be evaluated. Forecasts for overall CTC biomarker market estimate a big market with a high demand for innovative products with expected revenue potential of US$ 12bn in 2020. Due to the obvious relevance of cancer diseases for patients, their families as well as economic implications, Maintrac will have an important impact on future cancer disease management.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAINTRAC-AUTO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAINTRAC-AUTO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More